ARKG ETF (ARK Genomic Revolution ETF) is managed by Ark Invest with $1.69B in net assets. ARKG expense ratio is 0.75%, holding 33 positions across sectors including Health Care, Information Technology, Unknown. Inception date: 2014-10-31.

ARKG performance shows a YTD return of 47.36%. The 1-year return is 65.41% and the 5-year return is -15.69%.

ARKG top holdings include Tempus Pe (9.4%), Twist Bioscience Corp. (9.0%), Crispr Therapeutics Ag (8.9%), 10x Genomics Inc. Class A (5.8%), Beam Therapeutics Inc (5.4%). View all ARKG holdings, sector breakdown, or dividend history.

ARKG can be compared against other funds using the overlap calculator or side-by-side comparison tool. ARKG alternatives are available via the screener, along with tax-loss harvesting opportunities.